This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
OPKO Health, Inc. (NYSE:OPK) is pleased to announce the appointment of David Okrongly, Ph.D. as president of its diagnostics business unit.
Dr. Okrongly brings to OPKO extensive experience developing and commercializing advanced diagnostic platforms. Prior to joining OPKO, Dr. Okrongly most recently served as chief operating officer of Exosome Diagnostics, Inc. where he was responsible for establishing product, platform and regulatory strategy for the company’s proprietary technology for purifying RNA derivatives from exosomes. Prior to this, Dr. Okrongly served as president and chief executive officer of Quanterix Corporation, leading the company in development of the first fully automated, single-molecule diagnostic platform with 1,000 times better sensitivity than ELISA. Dr. Okrongly was with Bayer Diagnostics, a subsidiary of Bayer AG (ETR: BAYN), for over nine years and led the unit’s global R&D organization, launching industry-leading platforms in immunoassay, hematology, clinical chemistry and molecular diagnostics. While at Bayer Diagnostics, he also served as senior vice president in charge of the Molecular Diagnostics business unit. Dr. Okrongly received his Bachelors’ degree from the University of Wisconsin-Madison and his Ph.D. from Columbia University, both in Chemistry.
“David’s profound industry knowledge will be invaluable as we near the U.S. commercial launch for our 4Kscore™ prostate cancer diagnostic test, advance the development of our point of care diagnostic platform, and continue to execute our strategy of establishing industry-leading positions in large and rapidly growing medical markets,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. “We are extremely pleased to welcome David to OPKO.”
About OPKO Health, Inc.
OPKO is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies. For more information, visit
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including all non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies, prospects, growth opportunities, and management. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, and risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and, except as required by applicable law, we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.